1	The association of neutralizing antibodies with protection against
2	symptomatic dengue virus infection varies by serotype, prior infection
3	history, and assay condition
4	
5	Sandra Bos ^{1,#*} , Aaron L. Graber ^{1,#} , Jaime A. Cardona-Ospina ¹ , Elias M. Duarte ¹ , Jose Victor
6	Zambrana ^{2,3} , Jorge A. Ruíz Salinas ² , Reinaldo Mercado-Hernandez ¹ , Tulika Singh ¹ , Leah C.
7	Katzelnick ⁴ , Aravinda de Silva ⁵ , Guillermina Kuan ^{2,6} , Angel Balmaseda ^{2,7} , Eva Harris ¹ *
8	
9	[#] These authors contributed equally
10	*Co-corresponding authors
11	
12	¹ Division of Infectious Diseases and Vaccinology, School of Public Health, University of California,
13	Berkeley, Berkeley, CA, USA
14	² Sustainable Sciences Institute, Managua, Nicaragua
15	³ Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI,
16	USA
17	⁴ Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of
18	Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
19	⁵ Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA
20	⁶ Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua
21	⁷ Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de
22	Salud, Managua, Nicaragua

23 Abstract

24 The four dengue virus serotypes (DENV1-4) are the most prevalent arboviruses in humans and 25 a major public health concern worldwide. Understanding immune mechanisms that modulate 26 DENV infection outcome is critical for epidemic preparedness and development of a safe and 27 effective vaccine. Neutralizing antibodies (nAbs) are an essential component of the protective 28 response, yet their measurement often relies on a single cellular substrate and partially mature 29 virions, which do not capture the full breadth of neutralizing activity and may lead to biased 30 estimations of nAb potency. Here, we investigated the characteristics of nAbs associated with 31 protection against dengue cases using samples collected after one or more DENV infections but 32 prior to subsequent symptomatic or inapparent DENV1, DENV2, or DENV3 infections from a long-33 standing pediatric cohort study in Nicaragua. By assessing nAb responses using Vero cells with 34 or without the attachment factor DC-SIGN and with mature or partially mature virions, we found 35 that nAb potency and the protective NT₅₀ cutoff were greatly influenced by cell substrate and virion 36 maturation state. Additionally, the correlation between nAb titer and protection from disease 37 depended on an individual's prior infection history and the subsequent infecting DENV serotype. 38 Finally, we uncovered variations in nAbs composition that contributed to protection from 39 symptomatic DENV infection differently after primary and secondary prior infection. These 40 findings have important implications for identifying antibody correlates of protection in the context 41 of vaccines and natural infections.

42 Introduction

43 The four dengue virus serotypes (DENV1-4) are mosquito-borne flaviviruses endemic to 44 tropical and subtropical regions that cause the most prevalent arthropod-borne viral disease in 45 humans. Up to 100 million people are infected each year, of whom approximately 50 million 46 develop symptoms ranging from self-limiting but debilitating dengue fever to potentially fatal 47 dengue shock syndrome¹. Infection with one of the four antigenically related DENV serotypes 48 leads to the production of type-specific antibodies, which are specific to the infecting serotype, as 49 well as cross-reactive antibodies that can bind to other DENV serotypes. These cross-reactive 50 antibodies can either provide protection or increase the risk of subsequent symptomatic or severe DENV infection after both natural infections and vaccines^{2–6}. The occurrence of such adverse 51 52 events emphasizes the complexity of DENV immunity and the crucial need for a comprehensive 53 evaluation of correlates of protection to facilitate studies of natural infections and the development 54 of safe and effective DENV vaccines.

55 Neutralizing antibodies (nAbs) are essential for protection against dengue in both natural infections and vaccine trials^{5,7}. The composition and magnitude of pre-existing nAbs can vary 56 57 depending on the previous infecting serotype and number of previous infections $^{2-5}$. The current 58 "gold standard" to assess the neutralizing potential of nAbs are Plaque or Focus Reduction 59 Neutralization Tests (PRNT/FRNT), where serum/plasma samples are serially diluted to measure 60 viral infectivity⁸. Vaccine trials to evaluate correlates of protection usually perform DENV 61 neutralization assays according to the reference assay conditions with Vero cells as substrate 62 and WHO reference DENV strains grown in either mammalian (Vero) or insect (C6/36) cells⁸. 63 Although higher nAb titers correlate with a reduced risk of dengue disease, symptomatic dengue 64 cases can occur in individuals with relatively high nAb titers, suggesting that the current 65 neutralization assays may not adequately measure the types of nAbs critical for protection^{5,7}.

66 The DENV genome encodes three structural proteins -- envelope (E), precursor 67 membrane/membrane (prM/M), and capsid (C) -- that form the virion and seven nonstructural 68 proteins responsible for viral replication, assembly, and immune evasion⁹. Neutralizing antibodies

primarily target the envelope (E) protein of the virus, and nAb potency is influenced by the epitope they target. The epitope itself determines the required amount of antibodies to neutralize a viral particle (stoichiometry), and their efficiency varies depending on viral strain and physiological environment. Thus, several factors, including the temperature of incubation, the maturation state of the virion, the viral strain, and the choice of cell substrate impact the type of antibody measured. As a result, neutralization assay conditions can modulate nAb potency^{10,11} and the ability to measure antibody "repertoire" composition and functionality, referred to here as "quality".

76 DENV FRNT/PRNTs are commonly performed using DENV laboratory strains grown in Vero cells, which may not reflect the maturation state of virus circulating in human subjects¹⁰. 77 78 During viral assembly, immature particles are formed in the endoplasmic reticulum and 79 transported to the extracellular surface through the Golgi network, where they undergo 80 maturation. These immature particles are characterized by a spiky surface formed by trimeric prM-E heterodimers, with pr peptides capping the E fusion loop (FL)¹². Their transit through the 81 acidic compartment of the Golgi network results in a rearrangement of the E proteins (trimers to 82 dimers), and maturation occurs by cleavage of prM by the host protease furin^{13,14}. Upon release 83 84 into the neutral pH of the extracellular medium, the pr peptides detach, revealing the smooth 85 mature viral progeny that are infectious. However, maturation is not always complete. Areas 86 where pr has not been cleaved revert to trimeric spikes once virions are secreted, creating mosaic particles harboring different organizations of E proteins on their surface¹⁵. This difference in 87 maturation state changes the proportion and identity of epitopes exposed and, thus, the number 88 and type of antibodies required to completely neutralize infectious viral particles^{11,16}. 89

In addition, the cellular substrate of the neutralization assay is an important factor that can
influence neutralization potency, as it determines the host receptors relevant for viral entry. Unlike
other flaviviruses, the E protein of DENV has an additional glycosylation site at Asp-67 (E domain
I), which allows DENV to enter cells through interaction with the DC-SIGN attachment factor¹⁷.
DC-SIGN is expressed on dendritic cells (DCs) and monocytes, which account for the majority of
DENV-infected cells in the blood^{18–23}. DCs are potent antigen-presenting cells that mediate both
innate and adaptive immunity by producing cytokines and transporting antigens to secondary

97 lymphoid organs, where they prime naïve antigen-specific T cells. Nevertheless, in vitro studies 98 have shown that while DENV2-infected DCs can undergo activation and release of pro-99 inflammatory cytokines, they do not secrete IFN- α/β , which is critical for T cell priming²⁰. 100 Meanwhile, monocytes facilitate viral dissemination to various peripheral organs by acting as Trojan horses and transporting DENV virions to target tissues²⁴. DC-SIGN promoter 101 102 polymorphism in humans contributes to genetic susceptibility to DENV infection and is a risk factor 103 for developing severe dengue disease. As a result, efficient neutralization in the presence of DC-104 SIGN is important for limiting viral dissemination and for the establishment of a rapid and effective cell-mediated immune response²⁰. Evaluation of DC-SIGN-mediated entry in an FRNT/PRNT 105 106 assay enables a broad assessment of neutralizing potential of nAbs by measuring the impact of 107 nAbs that prevent N-glycan interaction and should be considered when investigating immune 108 correlates of protection.

109 Here, we used a set of plasma samples from our long-standing prospective pediatric 110 dengue cohort study in Nicaragua and evaluated the cross-reactive nAb response prior to 111 subsequent inapparent or symptomatic infections with DENV1, DENV2, or DENV3. We compared 112 neutralization potency across multiple assay conditions using partially mature and mature virions 113 on Vero cells and Vero cells expressing DC-SIGN. Using these four assay conditions, we 114 evaluated the nAb magnitude and guality associated with protection against symptomatic DENV 115 infection. We found that correlation with protection is dependent on the individual's prior DENV 116 infection history and the subsequent infecting serotype, as well as assay conditions. Further, we 117 show that comparison of nAb titers obtained with partially mature versus mature virions and 118 presence or absence of DC-SIGN can indicate the characteristics of antibodies that are important 119 for protection.

120 Materials and Methods

121 Ethics statement

122 The human subjects protocol for the Pediatric Dengue Cohort Study (PDCS) was reviewed and 123 approved by the Institutional Review Boards (IRB) of the University of California, Berkeley (2010-

124 09-2245), the University of Michigan (HUM00091606), and the Nicaraguan Ministry of Health 125 (CIRE-09/03/07-008). Parents or legal guardians of all subjects provided written informed 126 consent, and subjects 6 years of age and older provided assent.

127 Samples and study population

The PDCS is an ongoing open prospective cohort of 4,000 children 2-17 years old that was initiated in 2004^{6,25}. Blood samples are collected annually, and additional samples are collected from symptomatic suspected dengue cases at the acute (0-6 days post-onset of symptoms) and convalescent (14-21 days post-onset of symptoms) phase. DENV infections are evaluated and recorded yearly by comparing healthy annual serum/plasma samples collected in two consecutive years side-by-side by inhibition enzyme-linked immunosorbent assay (iELISA)². A \geq 4-fold increase in iELISA titer between annual samples is considered as indication of an infection²⁶.

135 Symptomatic dengue cases were confirmed by detection of DENV RNA by RT-PCR, real-136 time RT-PCR and/or virus isolation in the acute-phase sample; seroconversion of DENV-specific 137 immunoglobulin M antibodies in paired acute- and convalescent-phase samples; or a >4-fold 138 increase in antibody titer by iELISA between acute and convalescent sera^{2,27–29}. The serotype of symptomatic infections was determined by RT-PCR or real-time RT-PCR^{27,30,31}. Inapparent 139 140 infections were identified with a >4-fold increase in iELISA titer among participants who did not 141 present with illness to the study Health Center between annual samplings. In a subset, the 142 serotype responsible for the inapparent infections that occurred before 2016 was identified by 143 neutralization assays (DENV1-4) and/or a multiplex Luminex-based assay (E domain III [EDIII] of 144 DENV1-4 and ZIKV) by comparing the antibody profile in the annual samples collected before 145 and after the infection. Inapparent infections detected in 2016-2019 were attributed to DENV2 146 based on laboratory and epidemiological data showing the circulation of only DENV2 in Nicaragua 147 during these years.

We selected 127 DENV-immune children who subsequently developed an inapparent infection (n=64) or symptomatic infection (n=63) and analyzed their pre-infection plasma samples. Samples obtained after a single DENV infection are referred to as post-primary infection samples,

while samples obtained after two or more DENV infections are referred to as post-secondaryinfection samples (Figure 1).

153 Cell lines

Vero cells (ATCC CCL-81), Vero cells stably expressing human furin (Vero-Furin; kind gift of Victor Tse and Ralph Baric, University of North Carolina (UNC), Chapel Hill)³², and Vero cells expressing DC-SIGN (Vero DC-SIGN) were maintained in minimum essential medium (MEM; Gibco) with 5% fetal bovine serum (FBS) supplemented with 1X non-essential amino acids (Gibco), 1X sodium pyruvate (Gibco), and 1X penicillin-streptomycin (Gibco) at 37°C in 5% CO₂.

159 Generation of Vero DC-SIGN cell line

Vero cells were transduced using lentivirus to express DC-SIGN (CD209). DC-SIGN surface expression was confirmed by flow cytometry using a PE-conjugated mouse anti-CD209 antibody (BD Bioscience) for cell surface staining. A stock of Vero cells expressing surface DC-SIGN receptors at >95% was generated by cell sorting using the BD InfluxTM cell sorter and the BD FACSDivaTM 8.0.1 software (BD Biosciences).

165 Virus production

DENV1 (5575.10a1SPD1), DENV2 (8891.12a1SPD2) and DENV3 (6629.10a1SPD3) are clinical isolates from Nicaragua, isolated on C6/36 cells and passaged twice in Vero cells prior to production of working stocks. Partially mature and mature viruses were grown in Vero and Vero-Furin cells, respectively, in the same growth medium described above. Virions were harvested 5 days post-infection and frozen at 80°C until use.

171 Viral titer

Infectious titers were determined using a standard focus-forming assay³³. Briefly, Vero and Vero
DC-SIGN cells were infected with serial dilutions of virus and incubated at 37°C for 42-48 hours
(h) depending on the virus strain. Cells were fixed, permeabilized with 0.5% Triton for 6 minutes,

and stained with primary mouse anti-FL monoclonal antibody (mAb) 4G2 for 1.5h, washed 2 times
with PBS BSA 1%, and incubated with a goat anti-mouse secondary antibody conjugated to
horseradish peroxidase for 1h at room temperature. Foci were developed using True Blue HRP
substrate (KPL) and were counted using an CTL Immunospot analyzer (Cellular Technology,
Ltd.). The titer in focus forming units (FFU) per ml was then calculated based on the average of
replicates.

181 Viral genome quantification and calculation of infectivity

182 Viral RNA (vRNA) was extracted from virus particles using the QIAmp kit (QIAGEN). The PCR 183 standard curve used for the quantification of DENV copy genome was obtained with an amplicon 184 containing a synthetic cDNA encompassing a fragment of the 3'UTR region (nucleotides 10361-185 10660) from DENV2 NI15. Pan-DENV primers (F - TTGAGTAAACYRTGCTGCCTGTAGCTC; R 186 - GAGACAGCAGGATCTCTGGTCTYTC.) were used to amplify the 3'UTR region encompassing 187 nucleotides 10361–10660 of the genome of DENV clinical isolates used in this study. To assess 188 the proportion of infectious viral particles in each of the virus stocks, viral titers obtained in different 189 cell lines were plotted against the number of RNA copies present in each dilution of virus studied. 190 Specific infectivity was calculated as the number of RNA molecules required for each infection 191 event (vRNA:FFU).

192 Assessment of virion maturation state

193 For each serotype, equal numbers of vRNA genome equivalents (GE) of partially mature and 194 mature viral stocks were diluted in 6X Laemmli sample buffer, boiled at 95°C for 5 minutes, and 195 subjected to SDS-PAGE electrophoresis on a 4-20% gradient gel. Proteins were then transferred 196 to a PVDF membrane and blocked using a blocking buffer containing 5% non-fat milk in PBS + 197 0.1% Tween-20 (PBS-T). The membrane was incubated with a purified human anti-E FL mAb 198 (1M7) and anti-prM mAbs (2G3, 1E23 and 2H21) at 0.1ug/ml in blocking buffer at 4°C overnight. 199 Antigen-antibody complexes were detected using donkey anti-human IgG conjugated to 200 horseradish peroxidase (HRP; 1:5000, Biolegend) in blocking buffer for 1h at room temperature.

After washing, membranes were developed in Supersignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher). Western blot images were captured with a ChemiDoc XRS+ system (Bio-Rad). The pixel intensity of individual bands was measured using FIJI software, and relative maturation was calculated by using the following equation: (prM_{Vero Furin}/E_{Vero Furin})/(prM_{Vero}/E_{Vero}).

205 Neutralization assay

206 The focus reduction neutralization test (FRNT) assay was conducted using Vero or Vero DC-207 SIGN cells. Briefly, cells were seeded in a 96-well plate one day before infection. Serum/plasma 208 or mAbs were serially diluted and mixed with an equal inoculum of DENV (equivalent to 40-50 209 FFU/well for Vero and 150-200 FFU/well for Vero DC-SIGN cells) at a volume ratio of 1:1 to form 210 immune complexes. The virus-antibody mixture was incubated for 1h at 37°C in 5% CO₂. Cell 211 substrate growth medium was removed, and the virus-antibody mixture was added to Vero or 212 Vero DC-SIGN cells and incubated for 1h at 37°C in 5% CO₂. Subsequently, a 0.6% 213 carboxymethylcellulose overlay was added, and the plates were incubated for 48h. Foci were 214 developed and counted as described above. Foci counts were fitted using a variable slope dose 215 response curve using Graphpad, and neutralizing antibody titer (NT_{50}) values were calculated 216 with constrained top and bottom values of 100 and 0, respectively. Percent relative infection was 217 calculated as a ratio of foci counts in each serial dilution to the foci counts from the final serial 218 dilution of each sample. All samples and mAbs were run in duplicate with reported values required to have an $R^2 > 0.85$ and a Hill slope > 0.5. Neutralization titers were measured against the 219 220 heterotypic incoming serotype of each participant.

221 Statistical analysis

NT₅₀ values were obtained using GraphPad software as indicated above. Statistical analysis was performed in R software. Normal distribution of data was tested using the Shapiro-Wilk test. Adjusted p-values and statistical significance of nAb titer magnitude and differential NT₅₀ comparisons were computed using the Wilcoxon test with Benjamini Hochberg correction. Adjusted p-values and statistical significance of nAb potency across neutralization assay

conditions were computed using the paired Wilcoxon test with Benjamini Hochberg correction toidentify changes in antibody quality.

229 Receiver Operator Curve (ROC) analysis was performed using the pROC package 230 (v.1.18.0) in R studio (v. 2022.12.0+35). The pooled area under the curve (AUC), sensitivity and 231 specificity to detect a subsequent symptomatic infection was estimated across different assay 232 conditions. The cut-off of the assay was defined as the NT₅₀ value under which at least 90% of 233 the subsequent symptomatic infections were detected (sensitivity). The specificity corresponded 234 to the proportion of inapparent infections above this same value. A stratified analysis was also 235 conducted to evaluate the differential performance of the assay conditions according to incoming 236 infecting serotype (DENV1, DENV2 and DENV3). Finally, a logistic regression model was 237 constructed using the stats package v.4.2.2 and the oddsratio package v. 2.0.1 in R studio. We 238 assumed a binomial distribution of the response variable and a significance level (alpha) of 5%. 239 We estimated the odds ratio (OR) of developing a subsequent symptomatic versus inapparent infection given an increment of 10^2 in the NT₅₀. Power calculations were conducted using the *pwr* 240 241 package v. 1.3-0. The package pscl v 1.5.5 was used for estimating the McFadden's pseudo R-242 squared of each model.

243

244 **Results**

245 **Participants and DENV infections**

In this study, we analyzed pre-infection samples from 127 participants in the PDCS in Managua,
Nicaragua^{6,25}. These samples were collected 6-12 months before an inapparent DENV infection
(pre-inapparent group, n=64) or before a symptomatic infection (pre-symptomatic group, n=63)
(Fig.1). All participants included in the study had previously experienced DENV infection and had
developed anti-DENV antibodies (i.e., DENV-immune).

251 Characterization of virus maturation state and infectivity

To evaluate how the neutralization potency of serum antibodies is affected by DENV maturation state, we first generated partially mature and mature virion stocks using clinical isolates of

254 DENV1, DENV2, and DENV3 from Nicaragua. The maturation state of these virions was 255 confirmed by analyzing the prM content in each virus stock via Western blot analysis. We 256 observed significant prM levels in viruses grown in standard Vero cells, indicative of a partially 257 mature phenotype (Fig. S1A). In contrast, production of the same parental viruses in furin-258 overexpressing cells led to a substantial increase in maturation, as evidenced by low to 259 undetectable levels of prM (Fig. S1A). To further validate virion maturation state, we performed 260 FRNT using anti-FL mAbs (1M7, 4G2), which neutralize partially mature virions better than mature 261 virions¹⁰. As expected, virions grown in Vero-furin cells exhibited greater resistance to 262 neutralization by anti-FL mAbs, requiring higher concentrations for neutralization compared to 263 virions grown in standard Vero cells (Fig. S1C-D). These results demonstrated that viruses grown 264 in furin-overexpressing Vero cells were more mature than those grown in standard Vero cells. 265 Henceforth, we will refer to viruses grown in standard and furin-overexpressing Vero cells as 266 "partially mature" and "mature" virions, respectively.

267 We then evaluated the infectivity of both partially mature and mature DENV1, DENV2, and 268 DENV3 on standard Vero cells and Vero cells expressing the cellular attachment factor DC-SIGN. 269 This C-type lectin receptor plays a pivotal role in DENV biology by facilitating cell entry through 270 interaction with the N67 glycan on the envelope protein¹⁷. Viral infectivity was quantified by 271 determining the ratio of physical particle (vRNA) equivalents to focus forming units (FFU) (Fig. 272 S1B). As anticipated, the presence of DC-SIGN on the surface of Vero cells enhanced the 273 infectivity of both partially mature and mature DENV stocks, indicating that DC-SIGN provides an 274 alternative and potentially more favorable entry pathway for DENV. Importantly, the lowest 275 infectivity (10³-10⁴ vRNA:FFU) was observed using partially mature virions with standard Vero 276 cells, corresponding to the conditions of the reference neutralization assay. In contrast, the highest infectivity (10²-10³ vRNA:FFU) was observed using mature virions with Vero DC-SIGN 277 278 cells (Fig. S1B). These results show that under reference assay conditions, DENV virions exhibit 279 infectivity levels approximately ten times lower compared to conditions that more closely resemble 280 the DENV maturation state and entry pathway in vivo.

281

282 Cell substrate and DENV maturation state impact neutralization titer

283 Given the substantial influence of maturation state and cellular substrate/entry pathway on DENV 284 infectivity, we next wanted to evaluate how these parameters impact the measurement of 285 neutralizing antibody titers (NT_{50}), which are often used as a surrogate for protection against 286 dengue disease. To address this question, we used pre-infection samples from the 127 DENV-287 immune participants included in this study, collected prior to a subsequent DENV infection, and 288 evaluated how the neutralization potency of antibodies from each participant varied across four 289 assay conditions: partially mature DENV with Vero cells, partially mature DENV with Vero DC-290 SIGN cells, mature DENV with Vero cells, and mature DENV with Vero DC-SIGN cells (Fig. 2A). 291 In each case, NT₅₀ titers were measured against the heterotypic incoming serotype of each 292 participant and compared using a paired Wilcoxon test. For instance, the NT₅₀ of serum samples 293 from participants collected prior to a DENV1 infection was measured using DENV1, while the NT₅₀ 294 of serum samples from participants collected prior to a DENV2 infection was measured using 295 DENV2, etc.

296 Our results demonstrate that overall, NT_{50} values were significantly lower in assays 297 performed with mature virions compared to partially mature virions, indicating that serum 298 antibodies had a lower potency for neutralizing the incoming DENV virion in its mature form. 299 Additionally, NT₅₀ values were lower in assays performed on Vero DC-SIGN cells compared to 300 Vero cells (Fig. 2B), indicating a decrease in the potency of nAbs under conditions that facilitate 301 glycan-mediated DENV entry. Notably, the most significant difference in median NT_{50} values was 302 observed between assays performed using Vero cells infected with partially mature virions 303 (reference assay condition, NT_{50} =202) and those using Vero DC-SIGN cells infected with mature 304 virions (NT_{50} =42).

These findings underscore the significant impact of virion maturation state and cell substrate on the measurement of nAbs titers. Furthermore, they suggest that under reference assay conditions, the potency of cross-reactive nAbs from the same participant may be overestimated compared to neutralization assays performed with more mature virions and in the presence of DC-SIGN.

310 High pre-existing cross-reactive neutralizing antibodies titer is associated with protection

311 from dengue disease

312 We next investigated whether pre-infection nAb titers are associated with protection from dengue 313 disease. We compared the NT_{50} of pre-inapparent (n=64) versus pre-symptomatic (n=63) DENV 314 infection samples using the four assay conditions described previously. Our observations 315 revealed a significantly higher NT₅₀ in the pre-inapparent group, composed of individuals who 316 were protected against dengue disease, as compared to the pre-symptomatic group across all 317 four conditions, including the reference assay condition (Fig. 3A). This finding aligns with our 318 previous studies⁷ and supports that, overall, higher nAb titers are associated with protection from 319 symptomatic dengue.

320 To further analyze whether the NT_{50} magnitude was associated with lower risk of a 321 subsequent symptomatic DENV infection, we performed a logistic regression model for each 322 assay condition. Consistently, a higher NT₅₀ was associated with lower risk of developing a 323 subsequent symptomatic disease when the assay was performed using partially mature virions 324 (OR 0.86, 95% Confidence Interval [CI] 0.75-0.96) or mature virions (OR 0.82, 95% CI 0.70-0.94) 325 on Vero cells, as well as for partially mature virions (OR 0.85, 95% CI 0.73-0.96) and mature 326 virions (OR 0.72, 95% CI 0.53-0.92) on Vero DC-SIGN cells (Table 3). Taken together, these 327 results demonstrate that higher pre-existing cross-reactive nAb titers are correlated with lower 328 risk of developing a subsequent symptomatic infection.

High cross-reactive neutralizing antibody titer is associated with protection from dengue disease in participants who have experienced a single prior DENV infection, but not in those who have had two or more DENV infections.

Next, we interrogated the impact of prior immunity on protection from subsequent dengue disease by stratifying participants by their infection history. At the time of sample collection, 75/127 participants had experienced a single DENV infection (primary infection), and 53/127 participants had experienced two or more DENV infections (secondary infection). In the pre-inapparent group, 34/64 individuals had previously experienced a primary infection, while 30/64 had previously had 337 secondary infection(s). In the pre-symptomatic group, 41/63 individuals had experienced a 338 previous primary infection and 22/63 had had secondary infection(s) (Table 1). Samples collected 339 from participants with prior primary infection will be referred to as "post-primary" (Post-1°), while 340 samples collected from participants who previously had had two or more DENV infections will be 341 referred to as "post-secondary" (Post-2°).

342 In participants with a prior primary DENV infection, we observed significantly higher NT_{50} 343 values in the pre-inapparent group compared to the pre-symptomatic group across all four 344 conditions (Fig. 3B). This suggests that high titers of cross-reactive nAbs are associated with 345 protection from disease upon a second DENV infection. However, in the post-secondary group, 346 both pre-inapparent and pre-symptomatic participants exhibited high NT₅₀ titers with no significant 347 difference in titer magnitude (Fig. 3B). Notably, we observed that the titers in participants from the 348 post-secondary pre-symptomatic infection group were as high as the titers observed in 349 participants with one prior infection who were protected against a subsequent symptomatic 350 infection (Post 1° pre-inapparent group) (Fig. 4B). This showed that high nAb titers alone are not 351 sufficient for conferring protection, implying that other aspects of the nAb response beyond 352 magnitude, or even beyond neutralization potency, may play a role in protection after secondary 353 DENV infection.

Consistently, in the post-primary infection group, the NT₅₀ assessed using Vero cells with partially mature virions (OR 0.75, 95% CI 0.58-0.93) and mature virions (OR 0.79, 95% CI 0.63-0.97), as well as the NT₅₀ assessed using Vero DC-SIGN cells with partially mature virions (OR 0.73, 95% CI 0.55-0.92) and mature virions (OR 0.31, 95% CI 0.12-0.65), were associated with lower risk of subsequent symptomatic DENV infection using our logistic regression model. However, in the post-secondary infection group, none of the NT₅₀ titers assessed were associated with protection.

Collectively, these findings highlight that the association between nAb titer magnitude and protection against symptomatic DENV infection depends on the infection history of participants. Moreover, they suggest that while robust production of cross-reactive nAbs (magnitude) is a critical factor in protection against a second DENV infection, it appears insufficient to confer

365 protection against subsequent infections. This implies that other nuanced aspects within or 366 beyond the nAb response might contribute more to protection in individuals with secondary DENV 367 infection histories.

368 Maturation state- and DC-SIGN-sensitive antibodies are potential drivers of symptomatic 369 infection outcome after secondary infection

In light of these observations, we leveraged the different assay conditions to gain insight into the composition of nAb response. To do so, we compared the neutralizing potency of nAbs from each participant across paired assay conditions. Specifically, comparison of the NT_{50} measured using partially mature *versus* mature virions was used to evaluate the contribution of antibodies that are maturation state-dependent, while comparison of NT_{50} measured on standard Vero *versus* Vero-DC-SIGN cells was used as a proxy to evaluate whether neutralization was mediated by antibodies capable of neutralizing DENV through N-glycan-mediated entry.

377 As previously mentioned, we did not observe any significant difference in the magnitude 378 of NT₅₀ from post-primary pre-*inapparent* infection individuals (i.e., protected) and post-secondary 379 pre-symptomatic infection individuals (i.e., not protected) across all four conditions tested. 380 Consequently, we found these two groups particularly intriguing and compared them, along with 381 post-secondary pre-symptomatic individuals, to investigate whether variations in nAb composition 382 were associated with different outcomes. (Fig. 4A, B). Among the characteristics that set the 383 group of pre-symptomatic participants apart, we found that, unlike both pre-inapparent infection 384 groups (Post-1° and Post-2°), the neutralization potency of post-secondary pre-symptomatic 385 infection samples was significantly lower when using mature virions compared to partially mature 386 virions in Vero cells (maturation-sensitive nAbs). Similarly, lower neutralization potency was 387 observed when using partially mature virions to infect DC-SIGN-expressing Vero cells compared 388 to standard Vero cells in post-secondary pre-symptomatic infection samples (see Fig. 4C). This 389 underscores the variations that exist in the composition of the nAbs between protected and 390 unprotected individuals. Specifically, serum samples from participants protected against dengue 391 disease were characterized by cross-reactive nAbs that exhibited equal potency against both 392 mature and partially mature virions in Vero cells, and in the presence or absence of DC-SIGN. In

contrast, the nAb repertoire/composition of sera from participants who experienced symptomatic
 infection (Post-2° pre-symptomatic) was marked by nAbs sensitive to maturation state and the
 presence of DC-SIGN.

This finding supports that factors beyond the magnitude of nAb titers may play a substantial role in conferring protection against symptomatic dengue disease and emphasizes the importance of considering antibody quality, in addition to magnitude, when studying correlates of protection against dengue disease.

400 Neutralizing antibody magnitude associates with protection against dengue disease in a 401 serotype-dependent manner

402 We next investigated if the association of cross-reactive nAb titer with disease protection was 403 similar when the infecting serotype was DENV1, DENV2 or DENV3. To address this question, we 404 stratified the analysis by incoming DENV serotype. Our study included 19 individuals with 405 subsequent post-primary DENV1 infections, 61 individuals with subsequent DENV2 infections, 406 and 47 individuals with subsequent DENV3 infections (Table 2). In the pre-DENV1 infection group 407 (Fig. 5A, top row), which includes only post-primary infection individuals, higher nAb titers were 408 observed in the pre-inapparent group using neutralization assays with mature virions on standard 409 Vero cells and partially mature virions on both standard Vero and Vero DC-SIGN cells.

In the pre-DENV2 infection group, significantly higher nAb titers were observed in the preinapparent individuals across all conditions (Fig. 5A, middle row) when samples were not stratified by infection history. However, after stratification (Fig. 5B), only nAb titers assessed in standard Vero and Vero DC-SIGN cells using mature virions were correlated with protection from symptomatic infection in the post-primary group (n=29) (OR 0.62, 95% CI 0.38-0.88; OR 0.09, 95% 0.01-0.52, respectively) and with mature virions in standard Vero cells in the post-secondary group (n=32) (OR 0.72, 95% CI, 0.5-0.95) (Fig. 5B and Table S1).

In contrast, in the pre-DENV3 infection group (Fig. 5A, bottom row), the magnitude of nAb
titers was not significantly different between subsequent symptomatic and inapparent infection
regardless of assay condition or infection history (Fig. S2).

In summary, our findings reveal serotype-specific variation in protection against dengue disease. Higher pre-infection levels of cross-reactive nAbs are associated with protection from symptomatic DENV1 and DENV2 infections. However, this association was not observed in the case of DENV3, suggesting that disease protection in the context of DENV3 infections might involve other aspects of the immune response.

425 Pre-infection neutralizing antibody composition differentially impacts outcome by DENV 426 serotype and infection history

427 To assess how variations in nAb composition in pre-infection sera relate to protection from symptomatic DENV infection for each serotype, we used paired Wilcoxon tests to compare the 428 429 neutralization potency of samples stratified by serotype across assay conditions. In post-primary 430 pre-DENV1, pre-DENV2, and pre-DENV3 symptomatic individuals (Fig. 6A,B,C; Fig. S3), we 431 observed significant differences in NT_{50} titer when FRNT assays were performed using partially 432 mature virions with standard Vero compared to Vero DC-SIGN cells. These findings indicate that 433 antibodies present in pre-symptomatic infection samples are less potent for neutralizing DENV 434 when cell entry is glycan-mediated (i.e., interacting with DC-SIGN on the target cell). This 435 suggests a difference in nAbs composition, with pre-symptomatic post-primary DENV infection 436 individuals having less nAbs able to block DC-SIGN-mediated entry. In contrast, in post-437 secondary pre-DENV2 infection samples (Fig. 6D), a significant reduction in NT₅₀ titer was 438 observed in pre-symptomatic infection samples when FRNT assays were performed in standard 439 Vero cells using partially mature versus mature DENV2 virions. This suggests a difference in nAbs 440 composition, with post-secondary pre-symptomatic DENV2 individuals having more nAbs 441 sensitive to maturation state. Interestingly, no difference in nAb guality was observed in post-442 secondary pre-DENV3 infections.

443 Assay condition impacts cross-reactive neutralizing antibodies titer cut-off to distinguish 444 subsequent inapparent and symptomatic DENV infections

445 Since the identification of individuals who will develop a subsequent symptomatic infection is

relevant for vaccine design, we evaluated the performance of the four assay conditions for detecting a subsequent symptomatic DENV infection. We performed a ROC analysis to compare the assay conditions in terms of their sensitivity and specificity (Table 3). The cut-off of the assay was defined as the NT_{50} value under which at least 90% of the subsequent symptomatic infections were detected (sensitivity). The specificity corresponded to the proportion of inapparent infections above the cut-off value.

452 Notably, we found a substantial impact of assay condition on the test performance for 453 discriminating individuals who would subsequently develop a symptomatic versus inapparent 454 infection. The NT₅₀ cut-off varied substantially, ranging from 180 for mature virions on Vero DC-455 SIGN cells to 898 for partially mature virions on Vero cells (Table 3), and the maximum specificity 456 achieved was only 32% for the assay performed on mature virions with Vero cells (Table 3). For 457 the assay performed on partially mature virions on standard Vero cells, which is the assay used 458 in most clinical trials for vaccine testing, the NT₅₀ cut-off for achieving a sensitivity of at least 90% 459 was 898.13. Nevertheless, at this titer, the specificity was only 8%. This means that, using this 460 assay, although more than 90% of the individuals had an NT_{50} below 898 before developing a 461 symptomatic DENV infection, 92% of the individuals that subsequently developed an inapparent 462 infection were also below this cut-off and yet were protected from disease.

463 When we stratified by infection history, all assay conditions effectively identified 464 subsequent symptomatic infections in the post-primary and post-secondary infection group with 465 at least 90% of sensitivity (Table 3). However, the specificity ranged from 29% to 35% in the post-466 primary infection group, and from 10% to 21% in the post-secondary infection group. Interestingly, 467 mature virions with Vero DC-SIGN cells displayed the best performance in both groups (Table 3). 468 This reveals that in the context of natural infection, assessment of nAb titers are appropriate 469 screening tests for identifying individuals at risk for developing subsequent symptomatic DENV 470 disease, but they perform poorly for detecting protected individuals with subsequent inapparent 471 infection.

472

473 **Discussion**

474 In this study, we analyzed 127 individuals with known infection history who experienced 475 subsequent inapparent or symptomatic DENV infection from our long-standing cohort in 476 Nicaragua. We evaluated the effect of previous primary or secondary DENV immunity on the 477 quantity and quality of the cross-reactive nAb response by controlling key parameters of the 478 neutralization assay. We also assessed the association of nAb titer under different assay 479 conditions with probability of symptomatic DENV1, DENV2 or DENV3 infection. While we 480 confirmed that nAb titers overall are associated with protection against symptomatic DENV 481 infection⁷, we found important differences by infection history (i.e., prior primary versus secondary 482 immunity) and incoming serotype. We also show that the ability of nAb titers to identify individuals 483 at risk depends on DENV maturation state and cellular substrate in the neutralization assay.

484 Neutralizing antibodies are considered an essential component of the protective response against flavivirus infections and are used to assess vaccine safety and efficacy^{34,35}. As a 485 486 guantitative functional antibody assay, the neutralization assay is considered the "gold standard" for quantifying and characterizing DENV nAbs⁸. However, in routine laboratory practice as well 487 as in clinical trials, it is common to use virions grown in Vero or C6/36 cells⁸, although it has been 488 489 shown that DENV virions purified directly from human blood or produced in primary cells using 490 monocyte-derived dendritic cells are more mature than virions grown in cell culture-adapted lines^{10,36}. To approach a virion state closer to the one observed during natural infection, furin-491 492 overexpressing cell lines were generated and used to produce mature flavivirus stocks with low 493 prM content^{36,37}. This difference in maturation state changes the proportion and identity of 494 epitopes exposed and, thus, the number and type of antibodies required to completely neutralize 495 infectious particles^{11,16}. Consistent with published literature, we observed that plasma samples 496 showed a significantly lower neutralizing activity on mature virions compared to partially mature 497 virions grown in Vero cells, suggesting that neutralization titers may be overestimated under standard FRNT conditions³⁸. 498

499 Glycan-mediated entry is an important aspect of DENV dissemination in humans^{39,40}, but 500 standard assay conditions using cells lacking C-type lectin receptors (e.g., DC-SIGN) do not

501 measure the contribution of nAbs that prevent N-glycan interactions. Unlike other flaviviruses, the 502 E protein of DENV has an additional glycosylation site at Asp-67 (EDI), which allows DENV to 503 enter cells through interaction with DC-SIGN¹⁷. As we and others have shown^{17,41}, DC-SIGN is a 504 key attachment factor for DENV and expressing it on the surface of Vero cells significantly 505 increases DENV infectivity. DC-SIGN is expressed on dendritic cells (DCs) and monocytes¹⁸⁻²⁰ 506 and is associated with DENV pathogenesis. Nevertheless, while nAbs that impede DC-SIGN-507 mediated viral entry could limit viral dissemination and promote the establishment of a rapid and effective cell-mediated immune response²⁰, this parameter is rarely considered when studying 508 509 antibody-mediated protection against dengue disease. In this study, we assessed the effect of 510 DC-SIGN expression on Vero cells to measure nAbs able to block the N-glycan-mediated entry 511 pathway. As expected, nAb titers were strongly affected (decreased) by the expression of DC-512 SIGN, and the reduction in cross-reactive nAb potency was even greater when assays were 513 performed using mature virions. Similar results were previously published using another flavivirus closely related to DENV, West Nile virus, together with DC-SIGNR expressing-cells¹¹. We found 514 515 that when mature virions are used with Vero DC-SIGN cells, 90% of the subsequent symptomatic 516 infections can be identified with a lower NT_{50} cutoff than with other assay conditions, particularly 517 in post-primary infections. This shows that more serum antibodies are required to neutralize in 518 vitro assays with more physiologically relevant viruses and cells. Thus, anti-DENV nAb titers are 519 likely overestimated when measured in standard Vero cell-based assays and virions with a 520 maturation state different from the virions that antibodies encounter in the bloodstream during 521 infection. These findings highlight the importance of selecting an appropriate cell substrate and 522 virion maturation state to support vaccine development and evaluate efficacy.

523 Consistent with previous reports^{7,42}, we observed significantly higher nAb titers in 524 participants before an inapparent DENV infection as compared to before a symptomatic DENV 525 infection when analyzing the entire sample set. However, after stratification by post-primary 526 versus post-secondary DENV infection history, we found that the magnitude of the nAb response 527 only significantly correlated with protection after prior primary infection, although the direction of 528 the effect was similar for post-secondary infections. Further, we observed differences in

529 association with infection outcome when stratifying by incoming serotype. Higher magnitude of 530 pre-infection nAb titer was associated with protection from subsequent symptomatic infection with 531 DENV1 or DENV2, but not with DENV3 in any of the assay conditions or infection histories. 532 Interestingly, in a recent study investigating potential additional antibody characteristics that could 533 play a protective role, we found that antibody-dependent complement deposition (ADCD) and 534 complement- and antibody-mediated virolysis were associated with protection from symptomatic disease in samples collected prior to a subsequent DENV3 infection⁴³. Here, we also found that, 535 536 while their nAb titer magnitude was similar, the neutralizing activity of post-secondary pre-537 symptomatic infection individuals was primarily driven by both DC-SIGN-sensitive and maturation 538 state-dependent Abs, while the neutralizing potency of post-primary pre-inapparent infection was 539 not. This suggests that variations in the composition of the antibody repertoire exist in the 540 protected versus unprotected groups and that a difference in nAb guality might be associated with 541 disease outcome.

542 In addition, while 90% of the subsequent symptomatic infections in our study had pre-543 infection NT_{50} titers below the NT_{50} threshold identified via ROC analysis, a substantial proportion of pre-inapparent infection individuals did not reach this cutoff either, yet they did not develop a 544 545 symptomatic infection. This suggests that although nAbs play a role in protection against 546 symptomatic disease, the magnitude of nAb titers is not a robust parameter to differentiate 547 protected individuals from those at risk of developing a symptomatic infection and that other 548 components of the immune response may play an even more important role. This suggests that the measurement of nAb guality and other antibody Fc functions such as ADCD or virolysis⁴³ may 549 550 serve as correlates of protection, which could be used in addition to neutralization assays toward 551 the design and evaluation of dengue vaccines, as well as other components of the immune 552 response such as T cells.

553 The strengths of our study include the unique sample set that allowed us to evaluate the 554 effects of neutralization assay condition on the outcome of DENV infection in natural populations. 555 Samples from diverse epidemics allowed us to observe the distinctions in contribution of cross-556 reactive nAbs to protection from subsequent symptomatic infection depending on infection history and incoming serotype, which have not been reported previously. We also used clinical isolates representing circulating strains in the study population, which is important because highly passaged reference strains are cell line-adapted and have accumulated mutations that can change their antigenic landscape^{10,44}. In contrast, many vaccine studies and research laboratories frequently use WHO reference strains that do not match the genotypic and phenotypic features of the contemporary DENV strains^{33,45}.

563 Nevertheless, our study has limitations. First, since we studied sequential DENV infections 564 in natural populations, we evaluated the role of cross-reactive nAbs in protection, but were not 565 able to assess type-specific nAbs, which are often the focus of studies of vaccine efficacy⁵. 566 Nonetheless, many of our findings and overall conclusions are relevant for studies of immune 567 correlates of dengue. Second, as our study population is from Nicaragua over a 15-year period. 568 our analysis is naturally limited to the circulating serotypes and epidemiology of DENV in the 569 timeframe and area of study. Further, we were not able to address the impact of different 570 sequences of infections in the composition of the nAb response due to small sample sizes of 571 specific serotype sequences. Third, although anti-DENV antibodies can also have infection-572 enhancing properties, we do not measure this here since we focus on studying the neutralizing 573 capacity of antibodies using cell substrates that do not express Fcy receptors that can mediate 574 antibody-dependent enhancement⁴⁶. Lastly, our current sample size is under-powered for the 575 predictive model of risk of symptomatic disease for incoming DENV1 or DENV3 infection. 576 Nonetheless, the observed differences in effect sizes imply that for achieving a power of at least 577 80% we would need only 28 pre-DENV1 infection individuals, in contrast with 231 pre-DENV3 578 infection individuals and a total of 222 individuals in the post-secondary infection group. These 579 differences in the required sample size are evidence of the potential negligible role of nAbs in 580 protection against DENV3 symptomatic infection and upon a post-secondary infection.

In conclusion, we have identified serotype-specific differences in the association of nAbs with protection against symptomatic infection. Higher NT₅₀ titers were associated with protection against symptomatic DENV infection in participants with one prior DENV infection, but only against DENV2 in those with multiple prior infections. nAbs were correlated with protection from 585 symptomatic DENV1 and DENV2 infections but not DENV3. Thus, the unique features of our 586 cohort sample set allowed us to identify the role of infection history in shaping the protective 587 potency of nAbs, as well as the relevance of the incoming serotype, ultimately revealing the 588 heterogeneity and the complexity of immune interactions among DENV serotypes. Comparing 589 different assay conditions, we found that maturation state- and DC-SIGN-sensitive nAbs may be 590 less protective against symptomatic DENV infection. More studies are needed to assess the 591 effects of these variables, as well as the impact of WHO reference strains compared to clinical 592 isolates, in the context of vaccine studies. Finally, although nAbs correlate with protection under 593 specific circumstances, our findings reveal that they do not capture the full breadth of the 594 protective immune response, thus implying an important role for other aspects of the antibody 595 and broader immune response in generation and evaluation of protection from symptomatic 596 dengue. Incorporating a broader range of immune parameters in serological assays will enable a 597 more comprehensive evaluation of immune correlates of protection.

598 Funding

599 This work was supported by the National Institute of Allergy and Infectious Diseases/National 600 Institutes of Health (NIAID/NIH) via grant P01AI106695 (E.H.). The PDCS study was supported 601 by NIAID/NIH grants U01AI153416 (E.H.) and U19AI118610 (E.H.), R01AI099631 (A.B.), the 602 Pediatric Dengue Vaccine Initiative grant VE-1 (E.H.) from the Bill and Melinda Gates Foundation, 603 and NIH subcontract HHSN2722001000026C (E.H.). L.C.K. was supported by the Intramural 604 Research Program of NIAID/NIH.

605 Acknowledgments

We are grateful for the PDCS participants and their families. We appreciate the hard work and dedication of the past and present members of the study team at the Centro de Salud Sócrates Flores Vivas, the Sustainable Sciences Institute in Nicaragua, and the Laboratorio Nacional de Virología in the Centro Nacional de Diagnóstico y Referencia. We thank Scott Biering and Richard Ruan for generating the Vero-DC-SIGN cells.

611 Author contributions

S.B and E.H conceived the project. S.B. and A.G. designed the experiments. A.G., E.D., R.M-H
and T.S. carried out the experiments. J.V.Z, J.A.R managed the clinical and laboratory databases
and organized the data for analysis. G.K and A.B. directed the cohort study. S.B, A.G, E.D, J.C.O,
L.K, A.S. and E.H contributed to the analysis and interpretation of the results. E.H. obtained
funding. S.B, A.G., J.C.O and E.H., wrote the manuscript with input from all authors. All authors
provided critical feedback and helped shape the research, analysis and manuscript.

618 Inclusion & Ethics

619 This research is embedded in a long-term 35-year close collaboration with Nicaraguan colleagues 620 that has included multiple aspects of scientific capacity building and enhancement, as well as 621 supporting improvement of physical research infrastructure. With regards to this study, local 622 Nicaraguan researchers were included throughout the research process – in study design, study 623 implementation, data ownership, and authorship of publications. Four of the authors on this 624 publication are from the local team in Nicaragua. The research is locally relevant, and this was 625 determined in collaboration with local partners in Nicaragua. We discussed roles and 626 responsibilities amongst collaborators ahead of the research, and we conducted capacity-building 627 in the form of additional on-site training of local researchers in virus production and neutralization 628 assays. The parent cohort study has been approved initially and every year thereafter (currently in its 20th year) by a local ethics review committee. This research does not result in stigmatization, 629 630 incrimination, discrimination, or otherwise personal risk to participants nor any health, safety, 631 security or other risk to researchers. Benefit sharing measures related to transfer of biological 632 materials been discussed with our partners in Nicaragua. Finally, we have taken local and regional 633 research relevant to our study into account in citations.

634 Data and Material availability

635 All data produced in the present study are available by request, as is required by the Institutional 636 Review Board-approved protocol for the Pediatric Dengue Cohort Study. Please contact Dr. Eva 637 Harris (eharris@berkeley.edu) and/or the committee for the Protection of Human Subjects at 638 University of California Berkeley (510-642-7461; ophs@berkeley.edu). Data analysis was 639 performed using R and packages that are publicly available. Any transfer of materials needs to 640 be approved by the IRB and by Dr. Harris and Nicaraguan researchers. Further, the samples in 641 question are from pediatric participants in our long-term cohort study and are therefore very 642 limited in volume. Thus, these materials are subject to restriction based on limited availability. For 643 more information, please contact Dr. Harris and/or the committee for the Protection of Human 644 Subjects at University of California, Berkeley.

645 **References**

- 1. Cattarino, L., Rodriguez-Barraquer, I., Imai, N., Cummings, D. A. T. & Ferguson, N. M.
- 647 Mapping global variation in dengue transmission intensity. *Sci. Transl. Med.* **12**, (2020).
- Katzelnick, L. C., Coloma, J. & Harris, E. Dengue: knowledge gaps, unmet needs, and
 research priorities. *Lancet Infect. Dis.* **17**, e88–e100 (2017).
- Salje, H. *et al.* Reconstruction of antibody dynamics and infection histories to evaluate
 dengue risk. *Nature* 557, 719–723 (2018).
- Katzelnick, L. C. *et al.* Zika virus infection enhances future risk of severe dengue disease. *Science* 369, 1123–1128 (2020).
- 5. Sabchareon, A. *et al.* Protective efficacy of the recombinant, live-attenuated, CYD
- tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. *Lancet* 380, 1559–1567 (2012).
- 657 6. Katzelnick, L. C. *et al.* Antibody-dependent enhancement of severe dengue disease in
 humans. *Science* **358**, 929–932 (2017).
- Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E. Neutralizing antibody
 titers against dengue virus correlate with protection from symptomatic infection in a
 longitudinal cohort. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 728–733 (2016).
- 8. Thomas, S. J. *et al.* Dengue plaque reduction neutralization test (PRNT) in primary and
 secondary dengue virus infections: How alterations in assay conditions impact
- 664 performance. *Am. J. Trop. Med. Hyg.* **81**, 825–833 (2009).
- 665 9. Kuhn, R. J. *et al.* Structure of dengue virus: implications for flavivirus organization,
 666 maturation, and fusion. *Cell* **108**, 717–725 (2002).
- Raut, R. *et al.* Dengue type 1 viruses circulating in humans are highly infectious and poorly
 neutralized by human antibodies. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 227–232 (2019).
- Mukherjee, S. *et al.* Mechanism and significance of cell type-dependent neutralization of
 flaviviruses. *J. Virol.* 88, 7210–7220 (2014).
- 12. Yu, I.-M. *et al.* Structure of the immature dengue virus at low pH primes proteolytic

- 672 maturation. *Science* **319**, 1834–1837 (2008).
- 673 13. Stadler, K., Allison, S. L., Schalich, J. & Heinz, F. X. Proteolytic activation of tick-borne
 674 encephalitis virus by furin. *J. Virol.* **71**, 8475–8481 (1997).
- 14. Li, L. *et al.* The flavivirus precursor membrane-envelope protein complex: structure and
 maturation. *Science* **319**, 1830–1834 (2008).
- 15. Plevka, P. et al. Maturation of flaviviruses starts from one or more icosahedrally
- 678 independent nucleation centres. *EMBO Rep.* **12**, 602–606 (2011).
- 16. Nelson, S. *et al.* Maturation of West Nile virus modulates sensitivity to antibody-mediated
 neutralization. *PLoS Pathog.* 4, e1000060 (2008).
- 17. Mondotte, J. A., Lozach, P.-Y., Amara, A. & Gamarnik, A. V. Essential role of dengue virus
- 682 envelope protein N glycosylation at asparagine-67 during viral propagation. J. Virol. 81,
- 683 7136–7148 (2007).
- 18. Schmid, M. A., Diamond, M. S. & Harris, E. Dendritic cells in dengue virus infection: targets
 of virus replication and mediators of immunity. *Front. Immunol.* 5, 647 (2014).
- Hacker, K., White, L. & de Silva, A. M. N-linked glycans on dengue viruses grown in
 mammalian and insect cells. *J. Gen. Virol.* **90**, 2097–2106 (2009).
- 688 20. Rodriguez-Madoz Juan R., Bernal-Rubio Dabeiba, Kaminski Dorota, Boyd Kelley &
- 689 Fernandez-Sesma Ana. Dengue Virus Inhibits the Production of Type I Interferon in
- 690 Primary Human Dendritic Cells. J. Virol. **84**, 4845–4850 (2010).
- Durbin, A. P. *et al.* Phenotyping of peripheral blood mononuclear cells during acute dengue
 illness demonstrates infection and increased activation of monocytes in severe cases
 compared to classic dengue fever. *Virology* **376**, 429–435 (2008).
- Hall, W. C. *et al.* Demonstration of yellow fever and dengue antigens in formalin-fixed
 paraffin-embedded human liver by immunohistochemical analysis. *Am. J. Trop. Med. Hyg.*45, 408–417 (1991).
- 23. Jessie, K., Fong, M. Y., Devi, S., Lam, S. K. & Wong, K. T. Localization of dengue virus in
 naturally infected human tissues, by immunohistochemistry and in situ hybridization. *J.*
- 699 Infect. Dis. **189**, 1411–1418 (2004).

- Schmid, M. A. & Harris, E. Monocyte recruitment to the dermis and differentiation to
 dendritic cells increases the targets for dengue virus replication. *PLoS Pathog.* 10,
 e1004541 (2014).
- 25. Kuan, G. et al. The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods,
- Use of Information Technology, and Extension to Other Infectious Diseases. Am. J.
- 705 *Epidemiol.* **170**, 120–129 (2009).
- Gordon, A. *et al.* The Nicaraguan pediatric dengue cohort study: incidence of inapparent
 and symptomatic dengue virus infections, 2004-2010. *PLoS Negl. Trop. Dis.* **7**, e2462
 (2013).
- 27. Lanciotti, R. S., Calisher, C. H., Gubler, D. J., Chang, G. J. & Vorndam, A. V. Rapid
- 710 detection and typing of dengue viruses from clinical samples by using reverse
- transcriptase-polymerase chain reaction. J. Clin. Microbiol. **30**, 545–551 (1992).
- 712 28. Waggoner, J. J. *et al.* Homotypic Dengue Virus Reinfections in Nicaraguan Children. *J.*713 *Infect. Dis.* **214**, 986–993 (2016).
- 29. Balmaseda, A., Sandoval, E., Pérez, L., Gutiérrez, C. M. & Harris, E. Application of
- molecular typing techniques in the 1998 dengue epidemic in Nicaragua. *Am. J. Trop. Med. Hvg.* 61, 893–897 (1999).
- 30. Waggoner, J. J. et al. Development of an internally controlled real-time reverse
- transcriptase PCR assay for pan-dengue virus detection and comparison of four molecular
- dengue virus detection assays. J. Clin. Microbiol. **51**, 2172–2181 (2013).
- 31. Waggoner, J. J. *et al.* Single-Reaction Multiplex Reverse Transcription PCR for Detection of
- Zika, Chikungunya, and Dengue Viruses. *Emerg. Infect. Dis.* **22**, 1295–1297 (2016).
- 32. Tse, L. V. *et al.* Generation of Mature DENVs via Genetic Modification and Directed
- 723 Evolution. *mBio* **13**, e0038622 (2022).
- Martinez, D. R. *et al.* Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the
 Neutralization Activity of Human Antibodies in Vaccinees. *Cell Rep.* 33, 108226 (2020).
- 34. Dowd, K. A. & Pierson, T. C. Antibody-mediated neutralization of flaviviruses: a reductionist
- 727 view. Virology **411**, 306–315 (2011).

- 728 35. Pierson, T. C. & Diamond, M. S. Molecular mechanisms of antibody-mediated
- neutralisation of flavivirus infection. *Expert Rev. Mol. Med.* **10**, e12 (2008).
- 730 36. Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated
- from viremic patients infected with dengue virus. *Nat. Immunol.* **16**, 170–177 (2015).
- 732 37. Mukherjee, S. et al. Enhancing dengue virus maturation using a stable furin over-
- 733 expressing cell line. *Virology* **497**, 33–40 (2016).
- 38. Maciejewski, S. *et al.* Distinct neutralizing antibody correlates of protection among related
 Zika virus vaccines identify a role for antibody guality. *Sci. Transl. Med.* **12**, (2020).
- 39. Idris, F., Muharram, S. H. & Diah, S. Glycosylation of dengue virus glycoproteins and their
- interactions with carbohydrate receptors: possible targets for antiviral therapy. Arch. Virol.
- 738 **161**, 1751–1760 (2016).
- 40. Hidari, K. I. P. J. & Suzuki, T. Antiviral agents targeting glycans on dengue virus Eglycoprotein. *Expert review of anti-infective therapy* vol. 9 983–985 (2011).
- Tassaneetrithep, B. *et al.* DC-SIGN (CD209) mediates dengue virus infection of human
 dendritic cells. *J. Exp. Med.* **197**, 823–829 (2003).
- 743 42. Corbett, K. S. *et al.* Preexisting neutralizing antibody responses distinguish clinically
 744 inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. *J. Infect.*745 *Dis.* 211, 590–599 (2015).
- 746 43. Dias, A. G., Jr *et al.* Antibody Fc characteristics and effector functions correlate with
 747 protection from symptomatic dengue virus type 3 infection. *Sci. Transl. Med.* 14, eabm3151
 748 (2022).
- VanBlargan, L. A. *et al.* Dengue Virus Serotype 1 Conformational Dynamics Confers Virus
 Strain-Dependent Patterns of Neutralization by Polyclonal Sera. *J. Virol.* **95**, e0095621
 (2021).
- 45. Gallichotte, E. N., Baric, R. S. & de Silva, A. M. The Molecular Specificity of the Human
 Antibody Response to Dengue Virus Infections. *Adv. Exp. Med. Biol.* **1062**, 63–76 (2018).
- 46. Boonnak, K. *et al.* Role of dendritic cells in antibody-dependent enhancement of dengue
- 755 virus infection. J. Virol. **82**, 3939–3951 (2008).

756 Figure Legends

Figure 1. Participant serological sampling schematic. Plasma samples from DENV-immune participants were collected before a subsequent DENV1, 2, or 3 infection and were stratified into two separate groups according to disease outcome: Pre-inapparent (blue) and pre-symptomatic (yellow).

Figure 2. Cross-reactive nAb titers across assay conditions. (A) Schematic of the different neutralization assay conditions. (B) Neutralizing titers (NT_{50}) of 127 participants measured against the incoming DENV serotype using virions of different maturation state and different cell substrate. Median NT_{50} values are indicated below each boxplot. Diamond indicates mean NT_{50} . Asterisks indicate Benjamini Hochberg adjusted p-values for paired Wilcoxon test. p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

Figure 3. Cross-reactive nAb titers of pre-inapparent and pre-symptomatic DENV infection samples. (A) NT₅₀ of pre-inapparent (n=64) and pre-symptomatic (n=63) DNV infection groups measured against the incoming serotype across FRNT assay conditions, and (B) NT₅₀ of preinapparent and pre-symptomatic participants stratified by their infection history at the time of sample collection (Post-1°: post-primary infection, Post-2°: post-secondary infection). Diamond indicates mean NT₅₀. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test. p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

Figure 4. Comparison of nAb responses between pre-inapparent post-primary and postsecondary versus pre-symptomatic post-secondary infection samples. (A) Schematic of the groups compared. (B) Magnitude of the nAb response using different virion maturation states and cell substrates. (C) Impact of change in assay condition on the neutralization titers of participants. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test (B) and paired Wilcoxon test (C). p-values: ns, >0.05; *, <0.05; **, <0.01; ****, <0.001; ****, <0.0001.

780 Figure 5. Cross-reactive nAb titers of pre-inapparent and pre-symptomatic DENV infection

781 **participants stratified by incoming serotype and infection history.** (A) NT₅₀ of pre-inapparent

- and pre-symptomatic DENV infection groups across FRNT assay conditions stratified by incoming
- serotype. (B) NT₅₀ of pre-DENV2 infection participants stratified by infection history. Diamond
- ⁷⁸⁴ indicates mean NT₅₀. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test.
- 785 p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

786 Figure 6. Serotype-specific characteristics of the nAb response associated with DENV

787 **infection outcome.** Impact of change in assay condition on the nAb response of pre-inapparent

and pre-symptomatic infection participants from the (A) post-primary pre-DENV1 infection group,

(B) post-primary pre-DENV3 infection group, and (C) post-secondary pre-DENV2 infection group.

790 Post-1°: post-primary infection, Post-2°: post-secondary infection. Asterisks indicate Benjamini

Hochberg adjusted p-values for paired Wilcoxon tests. p-values: ns, >0.05; *, <0.05; **, <0.01;
, <0.001; *, <0.0001.









Vero Vero DC-SIGN Vero Vero DC-SIGN Β. Partially Mature Partially Mature Mature Mature Post 1° Post 2° Post 1° Post 2° Post 1° Post 2° Post 1° Post 2° 4 ns ns ns ns * ns ns ns NT50 (log10) 0 ALL O 0 0 ¢ 0 1 preprepreprepre-inapp. preprepreprepreprepreprepreprepresympt. inapp. sympt. inapp. sympt. sympt. inapp. sympt. inapp. sympt. inapp. inapp. sympt. inapp. sympt.



1

pre-inapp

pre-

sympt.

pre-inapp.

pre-

sympt.

pre-inapp.

pre-

sympt.

pre-

inapp.

pre-

sympt.



pre-inapp.

pre-

sympt.

pre-inapp.

pre-sympt.

pre-inapp.

pre-

sympt.

pre-inapp.

pre-

sympt.



Table 1. Pre-inapparent and pre-symptomatic infection participant characteristics.

	Pre-inapparent	Pre-symptomatic	р
n	64	63	
Age (mean (SD))	10.66 (2.81)	10.41 (3.56)	0.665
Male (%)	35 (55.6)	37 (60.7)	0.694
Infection history (%)			0.03
Primary (%)	34 (53.1)	41 (65.0)	
Secondary (%)	30 (46.9)	22 (35.0)	

Table 2. Participant characteristics stratified by incoming serotype and infection history

	DENV1	DENV2	DENV3	р
n	19	61	47	
Age (mean (SD))	9.93 (2.01)	11.29 (3.63)	9.83 (2.79)	0.044
Male (%)	11 (57.9)	34 (57.6)	27 (58.7)	0.994
Pre-symptomatic (%)	10 (52.6)	32 (52.5)	21 (44.7)	0.696
Pre-inapparent (%)	9 (47.4)	29 (47.5)	26 (55.3)	0.696
Infection history (%)				<0.001
Primary (%)	19 (100.0)	29 (47.5)	27 (57.4)	
Secondary (%)	0 (0.0)	32 (52.5)	20 (42.6)	

	AUC ^a	CI 95 ^b	Threshold (NT_{50})	Sensitivity	Specificity	OR ^c	CI 95
Combined							
Part.Mature ^d Vero	0.64	0.54 to 0.74	898.13	0.94	0.08	0.86	0.75 to 0.96
Mature Vero	0.62	0.52 to 0.72	475.83	0.9	0.32	0.82	0.70 to 0.94
Part.Mature ^d Vero DC-SIGN	0.65	0.55 to 0.75	701.95	0.9	0.14	0.85	0.73 to 0.96
Mature Vero DC-SIGN	0.64	0.54 to 0.74	180.25	0.9	0.29	0.72	0.53 to 0.92
Primary							
Part.Mature ^d Vero	0.68	0.56 to 0.81	392.70	0.9	0.29	0.75	0.58 to 0.93
Mature Vero	0.63	0.49 to 0.76	367.95	0.9	0.26	0.79	0.63 to 0.97
Part.Mature ^d Vero DC-SIGN	0.68	0.56 to 0.81	276.60	0.9	0.32	0.73	0.55 to 0.92
Mature Vero DC-SIGN	0.70	0.58 to 0.82	96.81	0.93	0.35	0.31	0.12 to 0.65
Secondary							
Part.Mature ^d Vero	0.54	0.37 to 0.71	981.84	1	0.10	ns	-
Mature Vero	0.59	0.43 to 0.75	767.76	1	0.17	ns	-
Part.Mature ^d Vero DC-SIGN	0.56	0.39 to 0.73	891.09	0.95	0.10	ns	-
Mature Vero DC-SIGN	0.54	0.38 to 0.70	455.15	0.91	0.21	ns	-

Table 3. ROC analysis and logistic regression of NT_∞ magnitude as a predictor for developing a subsequent symptomatic disease, stratified by infection history.

^aAUC = Area under the curve, ^bCl95 = 95% Confidence interval, ^cOR = Odds ratio, ^dPart. Mature = Partially mature virion.